Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia.

Loh ML.

Br J Haematol. 2011 Mar;152(6):677-87. doi: 10.1111/j.1365-2141.2010.08525.x. Review.

PMID:
21623760
2.

Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.

Chang TY, Dvorak CC, Loh ML.

Blood. 2014 Oct 16;124(16):2487-97. doi: 10.1182/blood-2014-03-300319. Epub 2014 Aug 27. Review.

3.

Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.

Loh ML.

Hematology Am Soc Hematol Educ Program. 2010;2010:357-62. doi: 10.1182/asheducation-2010.1.357. Review.

PMID:
21239819
4.

Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy.

Loh ML, Mullighan CG.

Clin Cancer Res. 2012 May 15;18(10):2754-67. doi: 10.1158/1078-0432.CCR-11-1936. Review.

5.

Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.

Koike K, Matsuda K.

Br J Haematol. 2008 May;141(5):567-75. doi: 10.1111/j.1365-2141.2008.07104.x. Epub 2008 Apr 13. Review.

PMID:
18422786
6.

Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.

Niemeyer CM, Kratz CP.

Br J Haematol. 2008 Mar;140(6):610-24. doi: 10.1111/j.1365-2141.2007.06958.x. Review.

PMID:
18302710
7.

[Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].

Sakashita K.

Rinsho Ketsueki. 2016 Feb;57(2):137-46. doi: 10.11406/rinketsu.57.137. Review. Japanese.

PMID:
26935631
8.

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.

Pérez B, Kosmider O, Cassinat B, Renneville A, Lachenaud J, Kaltenbach S, Bertrand Y, Baruchel A, Chomienne C, Fontenay M, Preudhomme C, Cavé H.

Br J Haematol. 2010 Dec;151(5):460-8. doi: 10.1111/j.1365-2141.2010.08393.x. Epub 2010 Oct 19.

PMID:
20955399
9.

Clinical characteristics of 15 children with juvenile myelomonocytic leukaemia who developed blast crisis: MDS Committee of Japanese Society of Paediatric Haematology/Oncology.

Honda Y, Tsuchida M, Zaike Y, Masunaga A, Yoshimi A, Kojima S, Ito M, Kikuchi A, Nakahata T, Manabe A.

Br J Haematol. 2014 Jun;165(5):682-7. doi: 10.1111/bjh.12796. Epub 2014 Mar 4.

PMID:
24588411
10.

Juvenile myelomonocytic leukemia.

Satwani P, Kahn J, Dvorak CC.

Pediatr Clin North Am. 2015 Feb;62(1):95-106. doi: 10.1016/j.pcl.2014.09.003. Review.

PMID:
25435114
11.

Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.

Bunda S, Kang MW, Sybingco SS, Weng J, Favre H, Shin DH, Irwin MS, Loh ML, Ohh M.

Cancer Res. 2013 Apr 15;73(8):2540-50. doi: 10.1158/0008-5472.CAN-12-3425. Epub 2013 Feb 11.

12.

Diagnosis and treatment of juvenile myelomonocytic leukemia.

Sakashita K, Matsuda K, Koike K.

Pediatr Int. 2016 Aug;58(8):681-90. doi: 10.1111/ped.13068. Review.

PMID:
27322988
13.

How I treat juvenile myelomonocytic leukemia.

Locatelli F, Niemeyer CM.

Blood. 2015 Feb 12;125(7):1083-90. doi: 10.1182/blood-2014-08-550483. Epub 2015 Jan 6. Review.

14.

[Molecular mechanism and treatment of juvenile myelomonocytic leukemia (JMML)].

Manabe A.

Rinsho Ketsueki. 2012 Aug;53(8):729-33. Review. Japanese. No abstract available.

PMID:
22975811
15.

Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.

Yoshida N, Doisaki S, Kojima S.

Paediatr Drugs. 2012 Jun 1;14(3):157-63. doi: 10.2165/11631360-000000000-00000. Review.

PMID:
22480363
16.

Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.

Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.

17.

Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia.

Bresolin S, Zecca M, Flotho C, Trentin L, Zangrando A, Sainati L, Stary J, de Moerloose B, Hasle H, Niemeyer CM, Te Kronnie G, Locatelli F, Basso G.

J Clin Oncol. 2010 Apr 10;28(11):1919-27. doi: 10.1200/JCO.2009.24.4426. Epub 2010 Mar 15.

PMID:
20231685
18.

[Juvenile myelomonocytic leukemias].

Lachenaud J, Strullu M, Baruchel A, Cavé H.

Bull Cancer. 2014 Mar;101(3):302-13. doi: 10.1684/bdc.2014.1908. Review. French.

PMID:
24691193
19.

Targeting RAS signaling pathways in juvenile myelomonocytic leukemia.

Flotho C, Kratz C, Niemeyer CM.

Curr Drug Targets. 2007 Jun;8(6):715-25. Review.

PMID:
17584027
20.

Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.

Hall J, Foucar K.

Int J Lab Hematol. 2010 Dec;32(6 Pt 2):559-71. doi: 10.1111/j.1751-553X.2010.01251.x. Review.

PMID:
20670271

Supplemental Content

Support Center